Pfizer Ruxience [legacy through FY23] by Year

Name: Pfizer Ruxience [legacy through FY23] by Year (PFE)
Creator: Pfizer

Ruxience (rituximab biosimilar) [legacy through FY23] — Worldwide revenues ($M) ($M)

Quarterly Annual

Pfizer Ruxience [legacy through FY23]: $26M in FY2023, up 23.8% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023

Period ended Dec 31, 2023

Change on a year earlier

+23.8%

21 in FY2022

History

6 years

Since FY2018

Sources

Documents cited below

Where the FY2023 figure comes from

“|| Ruxience | 26 | 21 | 23% | 22% | 33 | 25 | 35% | 41% | 23 | 9 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Ruxience (rituximab biosimilar) [legacy through FY23] — Worldwide revenues ($M) ($M)	Year on year	Source
FY2023	Dec 31, 2023	26	+23.8%	Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2022	Dec 31, 2022	21	+16.7%	Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021	Dec 31, 2021	18	+1,700.0%	Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020	Dec 31, 2020	1	-200.0%	Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019	Dec 31, 2019	-1	–	Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2018	Dec 31, 2018	0	–	Form 10-K (filed 2021-02-25) ↗

Breakdown

What makes up ruxience [legacy through FY23]

Cite this data

StockData. (2026). Pfizer Ruxience [legacy through FY23] ($M), annual FY2018–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/ruxience-leg-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.